ASCO 2020 Virtual is happening from May 29 to May 31, and it is exciting to watch major Oncology Pharmaceutical companies and their key presentations.
GSK, a leader in oncology R&D, has advanced its innovative pipeline by focusing on science related to the immune system, the use of human genetics and cutting edge technologies that will advance the next wave of cancer therapies with the potential to transform outcomes for the patients.
At this year’s ASCO meeting, they will showcase presentations on investigational therapies, including belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer.
As per Delveinsight analysis, as monotherapy and in a combination of pembrolizumab ICOS has blockbuster potential and is expected to generate a noteworthy revenue of more than USD 1 billion in the coming years after the successful launch in the market.
Safety and Activity of Autologous T-Cells with Enhanced NY-ESO-1–Speciﬁc T-Cell Receptor (GSK3377794) in HLA-a*02 Previously treated and untreated patients with Metastatic/Unresectable Synovial Sarcoma: A Master Protocol Study Design (IGNYTE-ESO)
#TPS8555: Hematologic Malignancies— Plasma Cell Dyscrasia (Multiple Myeloma)
Open-Label Pilot Study of Genetically Engineered NYESO-1 Speciﬁc T-Cells (GSK3377794) alone or in combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma
#TPS6591: Head and Neck
INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell co-stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for FirstLine Treatment of PD-L1Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Ongoing Investigation in Head and Neck Squamous Cell Carcinoma:
GSK3359609 is an investigational ICOS agonist antibody that is designed to selectively enhance T-cell function and enable anti-tumour responses in patients. At ASCO we can see the key ﬁndings of the ongoing studies into the antitumour potential of targeting the ICOS receptor through this agonist antibody alone and in combination with immune checkpoint therapies for the treatment of head and neck squamous cell carcinoma.
Abstract #8502: Multiple Myeloma
Preliminary data from the DREAMM-6 study on the safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma
Abstract #6517: Head and Neck Squamous Cell Carcinoma (HNSCC)
Updated Analysis of the Inducible T-cell Co-stimulatory Receptor Agonist (ICOS), GSK3359609 (GSK609), Combination with Pembrolizumab (PE) in Patients (pts) with Anti-PD-1/L1 Treatment-naïve Head and Neck Squamous Cell Carcinoma (HNSCC)
INDUCE-1: Report on Safety Run-in Cohorts Combining the Inducible T-Cell Co-Stimulatory Receptor (ICOS) Agonist GSK3359609 (GSK609) with Platinum+5-FU Chemotherapy (5-FU/plat), with or without Pembrolizumab.